Immune Suppression Articles & Analysis: Older
38 news found
Fungal infections typically occur in people with a weakened or suppressed immune system, but exposure to elevated levels of fungi can cause other concerns for almost everyone. ...
“While most people taking a cruise or working on a commercial vessel probably don’t think about exposure hazards to the bacteria that causes the disease, anyone with a weakened or suppressed immune system is vulnerable to becoming infected if they breathe in a mist or water droplets that have been contaminated with the ...
In healthcare settings, CDC reports that it can be difficult to determine whether mucormycosis is healthcare-associated or whether the infections were acquired somewhere else. People with a weakened immune system are at a higher risk of getting mucormycosis by inhaling fungal spores or if the spores enter the skin through an injury. Various types of mucormycosis include: ...
Tofacitinib Citrate Tofacitinib Citrate is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It works by suppressing the immune system and reducing inflammation in the body. Tofacitinib Citrate is a selective inhibitor of Janus kinase (JAK) enzymes, which play a key role in immune response and ...
The enzyme DGKzeta is a lipid kinase that can down-modulate T-cell activation by catalyzing the conversion of diacylglycerol to phosphatidic acid, thus acting as a ligand-independent, intracellular immune checkpoint. An inhibition of DGKzeta has been demonstrated to enhance T-cell priming against suboptimal tumor antigens and has the potential to overcome multiple ...
ByBayer AG
Ligation of CD47 to SIRPα delivers a “don’t eat me” signal to suppress macrophage phagocytosis. Tumor cells frequently overexpress CD47 to evade macrophage-mediated destruction. ...
RGT-264 phosphate tablet is a highly potent and selective HPK1 inhibitor. HPK1 kinase activity suppresses the immune functions of a wide range of cells including T cells and dendritic cells (DCs) 1. ...
Immune-Onc retains global development and commercial rights to IO-108. ...
“Chris brings a wealth of industry experience to Immune-Onc at an exciting stage in the company’s evolution,” said Charlene Liao, Ph.D., chief executive officer of Immune-Onc. ...
Immune-Onc retains global development and commercial rights to IO-108 and IO-202. ...
The combination of IO-108 and anti-PD-1 may enable more patients across multiple solid tumor types to benefit from immune checkpoint inhibitors,” commented by Maggie Gu, China general manager of Immune-Onc. ...
This research revealed the importance of PAD4 protein in the migration of neutrophils, specialized white blood cells that serve as the first line of immune defense in the body, directly impacting both primary tumor growth and secondary malignant tumor spread. Both genetic deletion of PAD4 and pharmacological inhibition of PAD4 using Jubilant Therapeutic Inc’s novel ...
The novel technology, originally developed by Suzanne Ostrand-Rosenberg, Ph.D., Emeritus Faculty at UMBC, and member of BriaCell’s scientific advisory board, is titled “Soluble CD80 as a Therapeutic to Reverse Immune Suppression in Cancer Patients” and covered under USPN 8,956,619 B2 , USPN 9,650,429 B2 , and USPN 10,377,810 B2 . In animal ...
Cellular kinase assays showed narazaciclib’s highest inhibitory activity to be against CDK4/6, CSF1R, (supports pro-tumor immune suppression), and NUAK1/ARK 5 (associated with poor prognosis in multiple cancers and implicated in cancer cell migration, invasion, and metastasis). ...
In solid tumors, activation of LILRB2 by its ligands, including HLA-G, ANGPTLs, SEMA4A, and CD1d, induces a tolerogenic phenotype in myeloid cells, thereby suppressing T cell activation and promoting tumor immune evasion. ABOUT IO-108 IO-108 binds to LILRB2 with high affinity and specificity and blocks the interaction of LILRB2 with multiple ligands that are ...
£1 million grant will support first-in-human clinical trials of H-Guard Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the ...
It targets stem cell modulation by inhibiting LSD1 and modulates immune suppression with isoform selective HDAC6 inhibition. Preclinical research has demonstrated its synergistic anti-tumor activity, which is superior vs. either target alone and a favorable safety profile with no significant safety concerns or accumulation. ...
Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard technology. ...
LAIR1 is activated by collagen which is highly abundant in the stroma of many solid tumor types and is thought to contribute to immune suppression. The data being presented suggest that LAIR1 antagonist antibodies reverse collagen-mediated immune suppression on T cells and myeloid cells in the solid tumor microenvironment, ...
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the Company will present at the virtual LILRB/ILT Symposium: A Deep Dive into Myeloid Checkpoint Therapeutics in Cancer on Tuesday, April 26, 2022, at 2:00 PM EDT, hosted ...